Subscribe To
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
Posters will feature preliminary Phase 1b combination data for potential best-in-class ERK1/2 inhibitor ERAS-007 with encorafenib and cetuximab or with palbociclib in patients with GI malignancies SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK […] The post Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Me...
Read More
Posted: Apr 26 2023, 21:00
Author Name: forextv
Views: 081966